Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Neuropharmacology. 2011 May 5;61(4):558–564. doi: 10.1016/j.neuropharm.2011.04.026

Figure 3. Fos and Fos-FG immunolabeling in mPFC subregions after drug challenge.

Figure 3

A – Schematic representation of FG microinjection sites in VTA, adapted from Paxinos and Watson (2007). Approximate injection location indicated by black dots; B – Representative photomicrograph of FG immunolabeling at injection site in VTA. Scale bar 100 μm; C – Fos-FG double-immunolabeling in mPFC after drug challenge; *p ≤ 0.05 vs. saline group; #p ≤ 0.05 vs. acute group; D – Representative photomicrograph of Fos and FG single and double-immunolabeling in mPFC. Black arrow indicates Fos immunolabeled cell; red arrow indicates FG immunolabeled cell; blue arrow indicates Fos-FG double immunolabeled cell. Scale bar 100 μm.